These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 22790919

  • 1. A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions.
    Hooper CE, Morley AJ, Virgo P, Harvey JE, Kahan B, Maskell NA.
    Eur Respir J; 2013 Jan; 41(1):18-24. PubMed ID: 22790919
    [Abstract] [Full Text] [Related]

  • 2. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [Abstract] [Full Text] [Related]

  • 3. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
    Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, Ferry BL, Lee YC.
    Am J Respir Crit Care Med; 2009 Sep 01; 180(5):437-44. PubMed ID: 19299498
    [Abstract] [Full Text] [Related]

  • 4. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
    Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A.
    Clin Biochem; 2009 Jul 01; 42(10-11):1046-50. PubMed ID: 19302997
    [Abstract] [Full Text] [Related]

  • 5. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.
    Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW.
    Thorax; 2007 Jul 01; 62(7):569-76. PubMed ID: 17356060
    [Abstract] [Full Text] [Related]

  • 6. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
    Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.
    Clin Cancer Res; 2007 May 15; 13(10):2928-35. PubMed ID: 17504993
    [Abstract] [Full Text] [Related]

  • 7. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
    Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T.
    Clin Chem Lab Med; 2011 Oct 15; 49(10):1721-6. PubMed ID: 21692685
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S.
    Cancer Invest; 2013 Jan 15; 31(1):43-50. PubMed ID: 23249166
    [Abstract] [Full Text] [Related]

  • 9. Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.
    Creaney J, Segal A, Olsen N, Dick IM, Musk AW, Skates SJ, Robinson BW.
    Dis Markers; 2014 Jan 15; 2014():413946. PubMed ID: 25505814
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
    Ferro P, Canessa PA, Battolla E, Dessanti P, Franceschini MC, Chiaffi L, Morabito A, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.
    Anticancer Res; 2013 Jun 15; 33(6):2707-13. PubMed ID: 23749930
    [Abstract] [Full Text] [Related]

  • 12. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
    Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R.
    Eur J Cardiothorac Surg; 2008 Apr 15; 33(4):723-7. PubMed ID: 18261916
    [Abstract] [Full Text] [Related]

  • 13. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
    Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P.
    Cancer Epidemiol Biomarkers Prev; 2009 Feb 15; 18(2):646-50. PubMed ID: 19190155
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
    Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP.
    Am J Respir Crit Care Med; 2010 Mar 15; 181(6):620-5. PubMed ID: 20075387
    [Abstract] [Full Text] [Related]

  • 15. Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
    Alemán C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de Sevilla TF.
    Med Clin (Barc); 2009 Oct 03; 133(12):449-53. PubMed ID: 19783262
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.
    Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW.
    Dis Markers; 2013 Oct 03; 35(2):119-27. PubMed ID: 24167356
    [Abstract] [Full Text] [Related]

  • 17. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
    Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK.
    Clin Cancer Res; 2011 Mar 01; 17(5):1181-9. PubMed ID: 21177406
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
    Villena V, López-Encuentra A, Echave-Sustaeta J, Martín-Escribano P, Ortuño-de-Solo B, Estenoz-Alfaro J.
    Cancer; 1996 Aug 15; 78(4):736-40. PubMed ID: 8756365
    [Abstract] [Full Text] [Related]

  • 19. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
    Creaney J, Dick IM, Segal A, Musk AW, Robinson BW.
    Lung Cancer; 2013 Dec 15; 82(3):491-8. PubMed ID: 24161718
    [Abstract] [Full Text] [Related]

  • 20. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.
    Mundt F, Nilsonne G, Arslan S, Csürös K, Hillerdal G, Yildirim H, Metintas M, Dobra K, Hjerpe A.
    PLoS One; 2013 Dec 15; 8(8):e72030. PubMed ID: 23991032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.